menu
    • menu
    [{"orgOrder":0,"company":"Panoptes Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Panoptes Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panoptes Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Panoptes Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Panoptes Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Panoptes Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Panoptes Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Panoptes Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Panoptes Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PP-OO1","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panoptes Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panoptes Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Panoptes Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Panoptes Pharma

    Menu

    Panoptes Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Panoptes Pharma

                            Austria arrow
                            OTS 2025
                            Not Confirmed

                            Panoptes Pharma

                            Austria arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PP-OO1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Viennese Biotech Company Panoptes Pharma Gmbh Has A Promising Active Ingredient Against COVID-19

                            Details : Panoptes Pharma GmbH has been able to demonstrate that COVID-19 treatment with PP-001 inhibits excessive release of certain cytokines.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2020

                            Lead Product(s) : PP-OO1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Panoptes Pharma

                            Austria arrow
                            OTS 2025
                            Not Confirmed

                            Panoptes Pharma

                            Austria arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PP-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers

                            Details : PP-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Keratoconjunctivitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 07, 2018

                            Lead Product(s) : PP-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Panoptes Pharma

                            Austria arrow
                            OTS 2025
                            Not Confirmed

                            Panoptes Pharma

                            Austria arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PP-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis

                            Details : PP-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Uveitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2018

                            Lead Product(s) : PP-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth